Target intelligence / Profile preview

Beta-galactosidase (BbrY_0422) (BbrY_0422)

Target
BbrY_0422
Molecular classification
Enzyme, Glycoside hydrolase family 42 (GH42)
01

Overview

BbrY_0422 is a specialized beta-galactosidase belonging to the Glycoside Hydrolase Family 42 (GH42), primarily identified in Bifidobacterium breve strain Yakult (YIT 4064). Unlike many generalist beta-galactosidases, BbrY_0422 exhibits high substrate specificity for 4'-galactosyllactose (4'-GL) and 4-galactobiose (4-GB), which are major components of prebiotic galacto-oligosaccharides (GOS). It notably lacks activity against lactose and other GOS isomers such as 3'-GL and 6'-GL, highlighting its role in a niche metabolic pathway. The enzyme is part of a genetic locus co-induced with an ABC transporter system (including the solute-binding protein BbrY_0420) that facilitates the uptake and intracellular breakdown of specific prebiotics. This metabolic capability is essential for the competitive colonization and persistence of B. breve in the human gut, particularly in infants. While not a traditional drug target, BbrY_0422 is a key focus in the development of targeted prebiotic therapies and the optimization of probiotic efficacy for improving gut health and preventing infections.

Other names
GH42 beta-galactosidaseBbrY_0422 glycoside hydrolase4'-galactosyllactose-specific beta-galactosidase
02

Mechanism of action

Hydrolysis of terminal non-reducing beta-D-galactose residues in beta-D-galactosides, specifically targeting the beta-1,4-glycosidic bond in 4'-galactosyllactose and 4-galactobiose.

03

Biological functions

Carbohydrate metabolismPrebiotic utilizationGalacto-oligosaccharide hydrolysis4'-galactosyllactose catabolism
04

Disease associations

Gastrointestinal healthInfection preventionInflammation modulation
05

Safety considerations

Generally recognized as safe (GRAS) as it is derived from a probiotic organism
06

Biomarkers

Bifidobacterium breve abundanceBbrY_0422 gene expression levels

Beyond the preview

Go deeper on Beta-galactosidase (BbrY_0422) (BbrY_0422).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-galactosidase (BbrY_0422) (BbrY_0422).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call